Terry O’Neal active positions
| Companies | Position | Start | End |
|---|---|---|---|
jCyte, Inc.
 jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Chief Administrative Officer | 01/07/2020 | - |
| Founder | 01/01/2012 | - | |
| Chief Operating Officer | 01/01/2012 | 01/07/2020 | |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Chief Operating Officer | - | - |
Career history of Terry O’Neal
Statistics
International
| United States | 3 |
Operational
| Chief Operating Officer | 2 |
| Chief Administrative Officer | 1 |
| Founder | 1 |
Sectoral
| Health Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
jCyte, Inc.
jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Health Services |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Terry O’Neal
- Experience
